TrialLupus science & medicine2021

Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.

Toni Maslen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.